Mosunetuzumab API is a recombinant, humanized bispecific monoclonal antibody developed for targeted immunotherapy in B-cell malignancies. It belongs to the class of CD20 × CD3 T-cell-engaging bispecific antibodies and is designed to simultaneously recognize CD20 on B cells and CD3 on T cells. By bringing T cells into close proximity with CD20-positive B cells, mosunetuzumab promotes T-cell activation and destruction of targeted B cells.
Mosunetuzumab is the active substance in Lunsumio. The European Medicines Agency identifies mosunetuzumab as the active substance and classifies it within the pharmacotherapeutic group of antineoplastic monoclonal antibodies and antibody drug conjugates. In the European Union, Lunsumio is indicated as monotherapy for adults with relapsed or refractory follicular lymphoma who have received at least two previous systemic therapies.
From a manufacturing perspective, mosunetuzumab is substantially different from conventional chemically synthesized small-molecule APIs. The current EMA assessment documentation describes it as a full-length humanized anti-CD20/CD3 immunoglobulin G1 (IgG1) isotype produced in Chinese hamster ovary (CHO) cells using recombinant DNA technology. Because it is a large biological molecule, its quality evaluation relies on biological and physicochemical characterization rather than the conventional chemical characterization used for low-molecular-weight APIs.
The molecular weight of mosunetuzumab is approximately 146 kDa. PubChem identifies CAS Number 1905409-39-3 and FDA UNII LDJ89SS0YG for mosunetuzumab. As a complex recombinant antibody, it does not have a simple molecular formula comparable to conventional small molecules such as C23H22N6O2.
Mosunetuzumab is engineered to bind two different cellular targets. One binding site recognizes CD20, a surface antigen expressed on B lymphocytes and many B-cell lymphoma cells, while the other recognizes CD3, a component of the T-cell receptor complex on T lymphocytes. This dual-binding mechanism enables mosunetuzumab to act as a T-cell engager and promote immune-mediated elimination of target B cells.
The approved medicinal product is supplied as a sterile concentrate for solution for infusion. Current European product information describes 1 mg/1 mL and 30 mg/30 mL presentations, both at a concentration of 1 mg/mL. The product is described as a clear, colourless liquid. The FDA labeling similarly identifies Lunsumio as a sterile, preservative-free product and reports a formulation pH of 5.8 for the finished medicinal product. These values describe the finished drug product, not necessarily a standalone bulk API specification.
Because mosunetuzumab is a biological API, appropriate quality assessment can involve identity, purity, aggregation, charge variants, glycosylation, potency, biological activity, host-cell proteins, residual host-cell DNA, process-related impurities, sterility and other critical quality attributes. The precise acceptance criteria are dependent on the applicable development stage, manufacturing process and approved regulatory specification and should therefore be taken from the relevant quality documentation rather than generic API assumptions.
Mosunetuzumab represents an important development in targeted immuno-oncology by combining antibody recognition of a B-cell antigen with direct T-cell engagement. Its established clinical application in follicular lymphoma and its recombinant antibody manufacturing platform make it relevant to biological drug development, formulation research and pharmaceutical manufacturing.
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | ≤ 1.5% |
| Water Content | NMT 1.0% |